Drug interactions between Pain-Eze Paracetamol Infant Drops Colour Free and Utira-C
|Pain-Eze Paracetamol Infant Drops Colour Free (acetaminophen)|
|Utira-C (hyoscyamine/methenamine/methylene blue/phenyl salicylate/sodium biphosphate)|
Interactions between your drugs
Applies to: Pain-Eze Paracetamol Infant Drops Colour Free (acetaminophen) and Utira-C (hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium biphosphate)
Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
For clinical details see professional interaction data.
Drug and food interactions
sodium biphosphate food
Applies to: Utira-C (hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium biphosphate)
Oral medications may not be properly absorbed when they are taken within one hour before starting sodium biphosphate for bowel cleansing. Talk to your doctor or pharmacist to see if you should adjust the dosing schedule of your other medications before you begin bowel cleansing treatment. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|